Anthony D. Elias, MD
Professor of Medicine
University of Colorado Cancer Center
Denver, Colorado
University of Colorado Cancer Center
Denver, Colorado
Adjuvant anti-HER2 therapy in combination with chemotherapy has markedly improved disease-free survival (DFS) and overall survival (OS) for patients with node-negative and node-positive HER2-positive breast cancer. The optimal use of trastuzumab (Herceptin, Genentech) appears to be giving it concurrently with chemotherapy, and then for 1 year as maintenance therapy. The roles of other anti-HER2